Metabometrix Business Overview
Current Investors
- Imperial College Innovations Ltd
- Renaissance Partners LP
- GeneLogic Inc
Business Model
Metabonomics has the power to positively impact the whole continuum of intervention- and prevention-based healthcare, from measurement of toxicity and efficacy potential in animals, to disease susceptibility, diagnosis, natural course, and effect of treatment in humans. In addition to its application in development of conventional medicines, the ability of metabonomics to reflect the changing status of the whole organism over time is ideal for evaluating age- and environment-related conditions, in which dietary and lifestyle adjustment may be key to either therapy or prevention.
In the pharmaceutical industry, the lack of effective, comprehensive screening techniques for efficacy and toxicity causes immensely wasteful loss of drug candidates in expensive and market-sensitive stages of development. Clinical trials of new therapeutic agents are hampered by insufficient biochemical definition of disease, the effects of existing treatments, and the lack of optimum markers of clinical outcomes.
Metabometrix’s business model is both dynamic and structured. Our strategy is:
To develop customised fee-generating activities in early screening of drug candidate safety and efficacy in animal models. Clients are principally pharmaceutical companies.
Concurrently to build very high value strategic alliances in disease areas with major multinational players in the pharmaceutical, nutraceutical and other healthcare industries. These alliances will be of substantial duration, addressing the entire natural lifespan of disease from susceptibility to clinical cure, and generate access fees, milestone payments, and potentially royalties or profit shares.
To commercialise key proprietary clinical markers that reflect and define the course of disease, via alliances with leading manufacturers of diagnostic test kits.
Investment Opportunities
Current funding targets are to increase capacity, in order to accelerate growth of our client base in the pharmaceutical and diagnostic industries. Selected corporate partners may also be invited to participate in the company’s equity.
|